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Fluid secretionIn polycystic kidney disease (PKD), intracellular cAMP promotes cyst enlargement by stimulating mural
epithelial cell proliferation and transepithelial ﬂuid secretion. The proliferative effect of cAMP in PKD is unique
in that cAMP is anti-mitogenic in normal renal epithelial cells. This phenotypic difference in the proliferative
response to cAMP appears to involve cross-talk between cAMP and Ca2+ signaling to B-Raf, a kinase upstream
of the MEK/ERK pathway. In normal cells, B-Raf is repressed by Akt (protein kinase B), a Ca2+-dependent
kinase, preventing cAMP activation of ERK and cell proliferation. In PKD cells, disruption of intracellular Ca2+
homeostasis due to mutations in the PKD genes relieves Akt inhibition of B-Raf, allowing cAMP stimulation
of B-Raf, ERK and cell proliferation. Fluid secretion by cystic cells is driven by cAMP-dependent transepithelial
Cl− secretion involving apical cystic ﬁbrosis transmembrane conductance regulator (CFTR) Cl− channels. This
review summarizes the current knowledge of cAMP-dependent cyst expansion, focusing on cell proliferation
and Cl−-dependent ﬂuid secretion, and discusses potential therapeutic approaches to inhibit renal cAMP
production and its downstream effects on cyst enlargement. This article is part of a Special Issue entitled:
Polycystic Kidney Disease.stic Kidney Disease.
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Renal cyst expansion in polycystic kidney disease (PKD) results from
aberrant proliferation of the cyst wall epithelial cells and accumulation
of ﬂuid within the cavity of the cyst. There is increased extracellular
matrix remodeling as the cyst invades the adjacentparenchyma, leading
to abnormal matrix deposition and ﬁbrosis. Several signaling pathways
have been implicated in the pathogenesis of PKD; however, intracellular
3′, 5′-cyclic adenosinemonophosphate (cAMP) has been shown to have
a central role in cyst growth by stimulating both epithelial cell
proliferation and transepithelial ﬂuid secretion. This review discusses
experimental evidence for cAMP-dependent cell proliferation, cAMP-
mediated Cl− and ﬂuid secretion, and potential approaches to reduce
renal cAMP and its effect on cyst enlargement.
2. Polycystic kidney diseases
Polycystic kidney diseases are a family of hereditary disorders
involving the formation and growth of innumerous cysts within thekidneys, often leading to end-stage renal disease (ESRD). Autosomal
dominant polycystic kidney disease (ADPKD) is the most common
form of PKDwith a frequency of 1 in 500–1000 births and accounts for
approximately 5–9% of all end-stage renal diseases (ESRD) (reviewed
in [1]). The disease is characterized by the formation of benign cysts
in ductal organs, chieﬂy the kidneys and liver, and other extrarenal
manifestations such as vascular aneurysms and cardiac valve defects.
In ADPKD, the kidneys become grossly enlarged to 4–8 times normal
size because of the progressive expansion of ﬂuid-ﬁlled cysts that
originate predominantly from collecting duct cells [2–6]. There is
a high degree of variability in the age of onset and rate of disease
progression evenwithin families, but generally there is signiﬁcant loss
of renal function by the ﬁfth to seventh decade of life. Approximately
one-half of ADPKD patients progress to chronic renal failure by age
60 and require dialysis or renal replacement therapy.
Autosomal recessive polycystic kidney disease (ARPKD) is a less
frequent childhood disease (approximately 1:20,000 live births) and is
characterized by cystic fusiform dilations of the renal collecting ducts,
accompanied by increased cell proliferation and ﬂuid secretion. Inmost
cases, cysts develop in utero and rapidly progress, causing massive
kidney enlargement and renal failure within the ﬁrst year of life.
Congenital hepatic ﬁbrosis is common in ARPKD and can cause
signiﬁcant clinical liver complication. Currently, there is no proven
treatment directed at the cellular defect responsible for ADPKD or
ARPKD.
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In ADPKD, every cell carries a mutated allele of either PKD1 or
PKD2; however, cysts appear in only a small fraction of the nephrons
and are thought to originate from clonal growth of single cells within
the tubules (Fig. 1). A somatic mutation or insufﬁcient expression of
the wild-type allele is thought to initiate renal cyst formation.
Mutations in PKD1 are responsible for 85% of the cases, and mutations
in PKD2 account for the remainder. The PKD1 gene encodes polycystin-
1 (PC1), a large protein that contains a large extracellular region, 11
membrane spanning domains and a relatively short intracellular C-tail
portion [7,8]. The extracellular region of PC1 contains protein motifs
that are predicted to be involved in cell–cell or cell–matrix interac-
tions, and/or possibly serve as a receptor for extracellular ligands [9].
The intracellular C-terminus has several predicted phosphorylation
sites and a conserved G-protein activation sequence [10,11]. A coiled-
coil domain mediates PC1 binding to polycystin-2 (PC2), the gene
product of PKD2 [12–14]. PC2, also called TRPP2, is a Ca2+ permeable
nonselective cation channel that localizes to different subcellular
compartments, including the endoplasmic reticulum (ER), plasma
membrane and the primary cilium. PC1 and PC2 may be part of
a protein complex that functions as a Ca2+ channel. Clinical and
cellular phenotypes of PKD1- and PKD2-initiated diseases are similar,
implicating a common signaling pathway for the two proteins [1].
In ADPKD, cyst formation begins in utero in a small fraction of renal
cells in which the level of PC1 or PC2 drops below a critical threshold
[3]. A somatic “second-hit” mutation, loss of heterozygosity or
haploinsufﬁciency may account for the mosaic nature of cyst
formation [15,16]. Cystic epithelial cells are characterized as being
incompletely differentiated and persistently proliferative, yet there is
an incomplete understanding of the linkage between the mutated
polycystins and the resultant abnormal proliferation or cellular
differentiation. Aberrant proliferation of tubule epithelial cells is
thought to cause the wall of the tubule to expand forming a mural
pocket. As the microscopic cyst expands in size, it ﬁlls with ﬂuid
derived from unreabsorbed glomerular ﬁltrate; however, once cysts
expand to approximately 2 mm in diameter, most become detached
from the parent tubule and become isolated sacs of ﬂuids, lined by an
epithelial cell layer [17]. These isolated cysts continue to expand
in size by the combination of mural epithelial cell proliferation and
transepithelial ﬂuid secretion (Fig. 1). ADPKD kidneys continue to
enlarge at a relatively constant rate after birth [18].
ARPKD is caused by genetic mutations in PKHD1, which encodes a
large protein, ﬁbrocystin (also called polyductin). The protein is
predicted to have a large extracellular domain, a single membranedividin
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Fig. 1. Schematic diagram illustrating the initiation and progression of cyst formation. In ADP
somatic mutation or insufﬁcient expression of non-mutated allele is thought to initiate cyst
stimulate cell proliferation and NaCl and water secretion causing cyst expansion [modiﬁedspanning domain and a short cytoplasmic tail [19–21]. The function of
ﬁbrocystin is unknown; however, in common with other proteins
associated with PKD pathogenesis [22], ﬁbrocystin localizes to
primary cilia of renal and biliary epithelial cells [20]. Cilia are thin
microtubule based structures that originate from one of a pair of
centrioles in the centrosome and extend from the apical surface into
the tubule lumen. Cilia are thought to transduce a Ca2+ signal in
response to mechanical stress, such as with ﬂuid ﬂow or chemical
stimulation [23]. Fibrocystin interacts with PC2, suggesting that it is
part of the same multi-protein complex as PC1 and PC2 to regulate
intracellular Ca2+ in response to external stimuli [24–26].
2.2. Dysregulation of intracellular calcium in PKD
The role of PC1, PC2 andﬁbrocystin in the regulation of intracellular
[Ca2+] and the processes by which mutations in their genes cause
epithelial cell hyperplasia and cyst formation remain unclear.
Converging evidence supports the hypothesis that disruption of
intracellular Ca2+ regulation and/or a reduction in steady-state Ca2+
levels contribute to cyst formation [27,28]. Cultured epithelial cells
derived from human ADPKD cysts have a basal [Ca2+]i approximately
20 nM lower than normal human kidney (NHK) cells [27]. Interest-
ingly, cells from tubules of non-cystic regions of early-stage ADPKD
kidneys have intracellular [Ca2+] similar to NHK cells, suggesting
that a germ-line mutation alone is insufﬁcient to cause a decrease in
intracellular Ca2+. ARPKD cells have also been shown to have reduced
levels of intracellular Ca2+ compared to NHK cells [27]. Furthermore,
PKHD1 gene silencing with siRNA leads to a 20 nM decrease in [Ca2+]i
[29], comparable to what is seen in human ADPKD cells. Reduction in
intracellular Ca2+ appears to be involved in cystogenesis in other
organs as well. Cholangiocytes derived from liver cysts of PCK rats,
an orthologous model of ARPKD, have reduced intracellular Ca2+
compared to normal biliary epithelial cells [30]. Thus, mutations in
both ADPKD and ARPKD genes appear to disrupt intracellular Ca2+
regulation, leading to a reduction in basal intracellular Ca2+ levels,
aberrant cell proliferation and cyst formation.
3. Regulation of renal intracellular cAMP
Cyclic AMP is one of the most ubiquitous second messengers and
is involved in the regulation of many biological processes including
cell proliferation, differentiation, transcription and electrolyte and
ﬂuid transport. Several lines of evidence have indicated that factors
that elevate renal intracellular cAMP promote cyst growth, kidney
enlargement and disease progression.apoptotic cellg cell
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Levels of intracellular cAMP are regulated by the activities of
adenylyl cyclases (ACs), which catalyze the formation of cAMP from
ATP, and phophodiesterases (PDEs) which degrade cAMP to AMP.
In most cells, basal cAMP levels are approximately 1 μM, whereas
a concentration of approximately 10 μM is needed to reach the
activation threshold for protein kinase A (PKA), a cAMP-dependent
serine/threonine kinase [31]. This threshold for cAMP activation of
PKA is achieved when extracellular ligands bind to heterotrimeric G-
protein-coupled receptors (GPCR) in the plasma membrane, followed
by activation of ACs. G-proteins are composed of an α-subunit, which
has a high afﬁnity for guanine nucleotides, and a tightly coupled β and
γ dimer [32].When a hormone binds to its receptor, GDP is exchanged
for GTP on the α-subunit, resulting in the release of the α-subunit
from the β/γ dimer. Both the α-subunit and the β/γ dimer can
interact with downstream effectors [33]. GTPase activity intrinsic to
the α-subunit hydrolyzes bound GTP to GDP causing reassociation of
α and β/γ subunits. Classiﬁcation of G-proteins is determined by the
subtype of the α-subunit (Gs, Gi, Gq and G12/13). The traditional view
of GPCR regulation of intracellular cAMP involves the regulation of AC
activity by stimulatory (Gsα) and inhibitory (Giα) G-proteins;
however, the β/γ dimermay also regulate certain AC isoforms [34,35].
Key features of cAMP signaling are cellular speciﬁcity and cellular
compartmentalization of the cAMP response [31]. Receptor expres-
sion and the unique combination of isoforms of ACs, PDEs and
regulatory proteins are important determinants of cell speciﬁcity for
the cAMP signal. There are nine closely related membrane associated
ACs, each with unique tissue distribution and biochemical properties
[36]. AC isoforms AC1, AC3, and AC8 are stimulated by Ca2+, whereas
AC5 and AC6 are inhibited by Ca2+. Thus, changes in intracellular Ca2+
levels may affect cAMP production, depending on which AC isoforms
are expressed. In the kidney, Ca2+-inhibitable AC5 and AC6, and Ca2+-
insensitive AC4 are the predominant isoforms [37]; however, other
isoforms are also expressed. AC3, an AC expressed in olfactory
neurons, is found in collecting ducts [38]. Recently, knockout of AC3
expression in AC3−/−mice reduced GFR, implicating a role for AC3 in
normal renal function [39]. In most cell types, the capacity for cAMP
hydrolysis greatly exceeds synthesis, indicating that cAMP levels are
generally regulated by the activity of PDEs. The PDE superfamily
consists of 11 structurally related gene families with over 60 isoforms
[40]. PDE1 and PDE4 are the predominant isoforms in collecting duct
cells; PDE1 is positively regulated by Ca2+-calmodulin.
Compartmentalization of the cAMP signal relies on cellular locali-
zation of ACs at the plasma membrane and A kinase-anchoring
proteins (AKAPs) which hold PKA to speciﬁc cellular compartments
in close proximity to the receptor, AC and PDE [41,42]. Detailed
understanding of the functional signiﬁcance of the multiplicity of the
cAMP-signaling components has yet to be resolved; however distinct
combinations of ACs, PDEs, PKAs and AKAPs are thought to allow
precise targeting of the cAMP signal and cross-talk with other
signaling systems. The localization of AKAPs close to the target protein
may also be necessary for speciﬁc and efﬁcient PKA phosphorylation
[43]. In addition to PKA, cAMP-dependent guanine nucleotide
exchange factors (EPacs) and cyclic nucleotide gated ion channels
are downstream effectors of cAMP and provide further diversity in the
cellular responses to cAMP stimulation [44–46].
3.2. Vasopressin stimulation of renal cAMP
Arginine vasopressin (AVP) is an important antidiuretic hormone
that stimulates cAMP production in collecting ducts and distal
nephron, the predominant sites for cyst formation in PKD [5]. AVP
binding to vasopressin V2 receptors (V2R) increases intracellular
cAMP and PKA phosphorylation of aquaporin-2 (AQP-2) water
channels, leading to AQP-2 activation and insertion into the apicalmembrane. Active AQP-2 channels increase the water permeability of
the collecting ducts, allowing water in the glomerular ﬁltrate to be
reabsorbed and returned to the circulation. When plasma osmolality
is greater than ~285 mOsm per kg, AVP is released from the pituitary
gland into the circulation. AVP increases water reabsorption, thus
decreasing urine volume and increasing urine osmolality. Shortly after
drinking a large volume of ﬂuid, AVP levels drop and urine becomes
diluted. In humans, urine osmolality typically exceeds that of plasma,
indicating that normal circulating AVP levels maintain cAMP in the
collecting duct cells to levels sufﬁcient to concentrate urine.
3.3. Elevated levels of renal cAMP in PKD
Renal cAMP levels are elevated in PKD animals, including pcy
mice, jck mice, PCK rats, and Pkd2WS25/− mice [47–50]. A potential
explanation for elevated renal cAMP in PKD kidneys is hyperactivation
of V2R in the cystic epithelial cells. It is widely accepted that renal
cysts in ARPKD originate from collecting ducts, where V2R are
predominantly expressed. ADPKD cysts arise in all nephron segments,
including the glomerulus; however, microdissection studies of ADPKD
kidneys have indicated that collecting duct derived cysts are more
numerous and larger [2]. Furthermore, the majority of ADPKD cysts
with diameters of 1 mm or greater stain positive for collecting duct
markers [5]. In Pkd1 and Pkd2 mouse models, cysts within postnatal
kidneys are predominantly of collecting duct origin [3,4,6]. Cells
cultured from human ADPKD cysts stain positive for collecting duct
lectins and express AQP-2 protein [51,52]. Both ARPKD and ADPKD
cells have a greater cAMP response to AVP and 1-deamino-8-D-
arginine vasopressin, a selective V2R agonist, than parathyroid
hormone (PTH) [53]. PTH receptors are expressed predominantly
in proximal convoluted and straight tubules, thick ascending limbs
of Henle's loop and distal convoluted tubules [54]. Thus, ARPKD and
ADPKD cell cultures appear to be enriched in cystic cells derived
from collecting ducts. Several studies have shown that V2R are
overexpressed in cystic kidneys of PKD animals [47,49,55,56],
suggesting that the cystic cells may be more responsive to AVP than
normal collecting duct cells. Moreover, there are increased levels
of circulating AVP in ADPKD and ARPKD patients possibly due to a
defect in the concentrating ability of the cystic kidney [57,58]. The
combination of increased V2R expression and increased circulating
levels of AVP may give rise to persistent cAMP production in cystic
epithelial cells of PKD kidneys.
It has also been suggested that a reduction in intracellular Ca2+,
secondary to mutations in the PKD genes, causes increased accumula-
tion of intracellular cAMP. Ca2+ reduction may increase the activity of
the Ca2+-inhibitable AC6 and decrease the activity of Ca2+/calmodulin-
dependent PDEs [59]. The combination of increased production and
decreased degradation of cAMP could raise basal concentrations of
cAMP to levels closer to the threshold for PKA activation. Consequently,
a higher resting cAMP level couldmake PKD cells more sensitive to V2R
stimulation and/or amplify the cAMP signal.
4. cAMP-dependent cell proliferation in PKD
Important to our understanding of cyst expansion is the discovery
that cAMP stimulates the proliferation of cyst epithelial cells derived
from human ADPKD kidneys while it inhibits the proliferation of
tubule cells from normal human kidneys [60,61]. cAMP agonists,
including AVP, accelerate ADPKD and ARPKD cell proliferation
through PKA stimulation of the mitogen-activated protein kinase
kinase/extracellular regulated kinase (MEK/ERK) pathway [52,62].
Virtually all of the stimulatory effect of cAMP is blocked by H-89, a
PKA inhibitor, and PD98059, a MEK inhibitor. In contrast, cAMP
inhibits ERK and proliferation of normal renal cells, including NHK and
M-1 cortical collecting duct cells [60,61]. Hence, elevated cAMP levels
alone are not sufﬁcient to promote renal epithelial cell proliferation.
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between intracellular [Ca2+] and cAMP in the regulation of the MEK/
ERK pathway in PKD [27,56,63].
4.1. cAMP regulation of the MEK/ERK pathway
The molecular mechanism for the phenotypic difference in the
cAMP mitogenic response between normal and PKD cells is linked to
the differential regulation of the Raf/MEK/ERK signaling pathway. B-
Raf, Raf-1 (also called C-Raf) and A-Raf are a family of serine/threonine
kinases that are central intermediates in transmitting extracellular
signals, including those from growth factors and hormones, to the
MEK/ERK pathway [64,65]. ERK activation is important for cell
proliferation during development and coordinates cell cycle re-entry
during tissue repair. Ras, small GTP-binding proteins (H-Ras, K-Ras, N-
Ras), recruit Raf to the plasma membrane which is essential for Raf
activation. In addition, Raf kinases are regulated bymultiple pathways
through phosphorylation of speciﬁc serine and threonine residues
[66]. The balance between the phosphorylation of stimulatory and
inhibitory sites is a major factor in Raf regulation of ERK-mediated cell
proliferation. Activated Raf phosphorylates and stimulates MEK1/2,
which in turn, phosphorylates and activates ERK1/2. There is
translocation of activated ERK into the nucleus where it upregulates
the transcriptional activity of a number of genes involved in cell
proliferation. The Raf/MEK/ERK pathway exerts its effects on cell
proliferation through induction of cell cycle regulatory proteins,
including the cyclin-dependent kinases (Cdks), cyclins and p21, and
transcription factors such as c-myc and AP-1 [67].
The capacity for cAMP to stimulate or inhibit ERK accounts for
many of the cell type-speciﬁc cAMP effects on cell proliferation
[68,69]. In astrocytes, smooth muscle cells, ﬁbroblasts and mesangial
cells, cAMP inhibits ERK activity and cell proliferation. On the other
hand, cAMP stimulates ERK and proliferation of other cell types,
including thyroid cells, hepatocytes and PC-12 neuronal cells [70].
Regulation of cAMP signaling to ERK occurs at the level of Raf. While
B-Raf and Raf-1 share homology in amino acid sequence, the two
kinases are differentially regulated by cAMP. Two activation sites in
Raf-1 (T491 and S494) are conserved in B-Raf (T599 and S602) [65],
and the phosphorylation of these residues is important for kinase
activity. However, unlike B-Raf, S338 and Y341 of Raf-1 must also be
phosphorylated for kinase activation. The corresponding serine
residue in B-Raf (S446) is constitutively phosphorylated and the
tyrosine residue at 341 (Y341) of Raf-1 is replaced in B-Raf with an
aspartic acid (D449), which mimics phosphorylated tyrosine. Conse-
quently, fewer phosphorylation events are necessary to activate B-Raf
compared to Raf-1. Another important difference is that Raf-1 has
three PKA inhibitory phosphorylation sites (S43, S233 and S259), any
one of which can block Ras binding to Raf-1 and prevent Raf-1
translocation to the membrane [71,72]. These PKA phosphorylation
sites are not conserved in B-Rafmaking B-Raf resistant to inhibition by
cAMP; instead, PKA phosphorylation stimulates B-Raf activity. In
addition, B-Raf has a greater afﬁnity for MEK and produces a stronger
MEK stimulation than Raf-1. Thus, B-Raf has higher basal activity
compared to Raf-1 [73] and seems to be poised for activation by cAMP.
The effect of cAMP on B-Raf signaling to MEK is cell type and/or
content dependent. There are twomajor isoforms of B-Raf (95 kD and
68 kD) generated by alternative splicing. Vossler et al. had suggested
that cAMP stimulates ERK in cells that express the 95 kD isoform of
B-Raf and inhibits ERK in cells lacking this isoform [74]. However, in
other reports, cAMP was shown to inhibit B-Raf in cells expressing
both isoforms, indicating that B-Raf regulation by cAMP may be
dependent on cellular conditions. In particular, B-Raf has been shown
tobenegatively regulated byAkt (also calledprotein kinaseB), a serine–
threonine kinase, through a Ca2+-dependent and phosphoinositide
3-kinase (PI3-kinase)-dependent manner [75–77]. Akt phosphorylates
B-Raf at S365 and T440, important sites for B-Raf inhibition, andmutations of residues near T440 prevent phosphorylation by Akt,
leading to a loss of Akt-mediated B-Raf inhibition. These mutations are
associated with activated ERK and increased cell proliferation in certain
cancers, including lung small cell carcinoma and malignant melanoma
[65,78].
4.2. Ca2+ regulation of cAMP-dependent ERKactivation and cell proliferation
Evidence indicating that PC1, PC2 and ﬁbrocystin normally
contribute to the regulation of intracellular Ca2+ led to the hypothesis
that a reduction in intracellular Ca2+ in cystic cells may be the basis
for cAMP-dependent cell proliferation. To test the role of Ca2+, NHK
cells and immortalized mouse collecting duct M-1 cells were treated
with Ca2+ channel blockers or EGTA, a Ca2+ chelator, to lower
intracellular Ca2+ levels [63]. In these experiments, Ca2+ restriction
converted the normal cAMP growth-inhibited phenotype to a cAMP
growth-stimulated phenotype, mimicking PKD cells. In these Ca2+-
restricted cells, cAMP stimulated B-Raf kinase activity and increased
phosphorylated ERK (P-ERK) and cell proliferation. Ca2+ restriction
decreased the level of phosphorylated Akt, which normally represses
B-Raf. Direct pharmacological inhibition of Akt also caused cAMP-
dependent activation ERK and cell proliferation. Moreover, stable
overexpression the C-terminal tail of PC1 in M-1 cells, which is
thought to act in a dominant negative manner, decreased intracellular
Ca2+, and switched the cAMP response, such that cAMP activated B-
Raf, ERK and cell proliferation [63]. Interestingly, the Ca2+ switch
required several hours, suggesting that additional Ca2+-dependent
mechanisms are involved.
In a reciprocal study, treatment of human ADPKD and ARPKD cells
with Bay K8644, a Ca2+ channel activator, or A23187, a Ca2+ ionophore,
caused a sustained increase in steady-state Ca2+ levels and completely
reversed the mitogenic response to cAMP, thus rescuing the normal
anti-mitogenic response to cAMP [27]. Untreated ADPKD cells had
lower basal Akt activity compared to NHK cells and raising intracellular
Ca2+ increased Akt activity and suppressed B-Raf, thereby blocking
cAMP-dependent ERK activation and cell proliferation. Taken together,
these studies support the hypothesis that a reduction in intracellular
Ca2+, secondary tomutations in the PKD genes (PKD1, PKD1 or PKHD1),
decreases Akt activity, relieving Akt inhibition of B-Raf, and allowing
cAMP activation of the B-Raf/MEK/ERK signaling and cell proliferation
(Fig. 2).
In further support of this hypothesis, Pkd2 overexpression in
collecting duct cells of a transgenic mouse caused formation of typical
renal cysts, possibly due to excess PC2 acting in a dominant negative
manner or due to an imbalance in the PC1 to PC2 stoichiometry [79].
These cysts had increased levels of P-ERK and cell proliferation that
were dependent on B-Raf. Moreover, there were reduced levels of
P-Akt in the cystic kidneys, consistent with the human ADPKD cells.
Akt regulation of B-Raf, ERK and cell proliferation in cystic biliary
epithelial cells in the PCK rat, an ARPKD model, appears to involve a
similar mechanism. Restoration of intracellular Ca2+ levels in cystic
cholangiocytes blocked cAMP-dependent activation of B-Raf, ERK and
cell proliferation in an Akt-dependent manner [30]. On the other
hand, it has been reported that Akt activity is increased in mitotic, but
not resting cells, in the proximal tubule-derived cysts of Cy/+ Han:
SPRD rats, a non-orthologous model of ADPKD [80]. It is possible that
additional pathways, including the Akt/mTOR signaling pathway, are
involved in cell proliferation in Cy/+ kidneys [80–82]. Additional
studies are needed to delineate the relationships among intracellular
Ca2+, Akt, B-Raf and cAMP-dependent activation of the MEK/ERK
pathways in PKD.
4.3. Ca2+ channel blockers in PKD animals
Ca2+ channel blockers (CCBs) are widely used for the treatment of
hypertension in chronic kidneydiseases, includingADPKD. Treatmentof
Fig. 2. Proposed signal transduction pathways for Ca2+ regulation of cAMP-dependent cell proliferation. Normally, cell proliferation is controlled by growth factors binding to
receptor tyrosine kinase with sequential activation of Ras→Raf-1→MEK→ERK to induce cell proliferation. There is a phenotypic difference between normal kidney cells and PKD
cells in the cAMP effect on proliferation. (A) In normal human kidney (NHK) cells, basal Ca2+ levels, regulated by a variety of Ca2+ entry mechanisms, including the PC1/PC2
complex, maintain the activity of PI3 kinase/Akt pathway which represses B-Raf. B-Raf kinase activity is inhibited by Akt phosphorylation of an inhibitory site. cAMP agonists, i.e.
AVP, inhibit Raf-1, ERK and cell proliferation through a PKA-dependent mechanism. Thus, in normal renal cells, the balance of positive and negative signals control Raf-1 signaling to
ERK activation and cell proliferation. (B) By contrast, in PKD cells a reduction in intracellular Ca2+ levels due to a loss of PC1/PC2 function relieves Akt inhibition of B-Raf, allowing
cAMP to signal through B-Raf to activate MEK and ERK and to stimulate cell proliferation [adapted from Cowley, Kidney Int. 73:251–253, 2008; and Yamaguchi et al., J. Am. Soc
Nephrol 17: 178–187, 2006].
1295D.P. Wallace / Biochimica et Biophysica Acta 1812 (2011) 1291–1300ADPKD cells with Ca2+ entry blockers were found to amplify cAMP-
dependent ERK activation and cell proliferation, raising the possibility
that treatment of ADPKD patients with CCBs might further reduce
intracellular Ca2+ and accelerate cyst growth. Three classes of L-type
anti-hypertensive CCBs (phenylalkylamines, benzothiazepines and
dihydropyridines) have different chemical characteristics, but are
generally thought to have similar actions to lower blood pressure. In a
preliminary study, Nutahara et al. compared the effects of candesartan,
an angiotensin II receptor blocker, and amlodipine, a dihydropyridine
L-type CCB, in a small cohort of ADPKD patients [83]. The study
suggested that angiotensin II receptor blockers are more effective thanCCBs for renal protection in ADPKD patients, independent of the
capacity to control hypertension. Blockade of the renin–angiotensin–
aldosterone system with angiotensin-converting enzyme inhibitor or
angiotensin receptor blockers have been shown to be more beneﬁcial
than other agents [84,85], although not all studies support this concept
[86]. More recently, Nagao et al. examined the effect of CCBs on the
growth of cysts and PKD progression by treating Cy/+ rats with
verapamil, a phenylalkylamine L-type CCB, twice daily from 5 to
12 weeks [56]. Verapamil treatment increased the renal activity of the
B-Raf/MEK/ERK pathway and accelerated renal cyst growth in Cy/+
rats, determined by increases in kidney volume, cystic area, PCNA
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restriction to accelerate cyst expansion in PKD, the impact of CCBs on
ADPKD progression remains to be tested.
5. cAMP-mediated Cl−-dependent ﬂuid secretion
The remarkable appearance of ADPKD kidneys is due to the
accumulation of ﬂuid within hundreds or thousands of cysts that
grossly enlarge total kidney volume. In the initial stages, cysts ﬁll with
ﬂuid derived from glomerular ﬁltrate; however, the majority of the
cysts larger than 2 mm in diameter have no connection to the nephron
segment from which they originated [17]. Within these isolated cysts,
transepithelial ﬂuid secretion is the only means by which solutes
and ﬂuid can accumulate. During the past 15 years, several lines of
evidence have determined that ﬂuid secretion is driven by active
transepithelial Cl− transport stimulated by cAMP [87].
The seminal observation for ﬂuid secretion was made by McAteer
et al., where Madin-Darby canine kidney (MDCK) cells were shown to
form ﬂuid-ﬁlled cysts when seeded in a collagen matrix [88]. Agonists
that stimulated the production of cAMP accelerated ﬂuid secretion
and in vitro cyst growth [89]. The use of the MDCK cell line has helped
to establish experimental procedures that have greatly facilitated
research on cAMP-dependent ﬂuid secretion using primary cultures of
human ADPKD cells [89–93]. An important study by Ye et al. showed
that intact cysts excised fromADPKDkidneys secreteﬂuidwhen treated
with forskolin, a direct activator of ACs [94], conﬁrming that intact
cyst epithelia secrete ﬂuid by mechanisms regulated by intracellular
cAMP.
As with other secretory epithelia, ﬂuid secretion by ADPKD cysts
is dependent on transporters and ion channels within the apical
and basolateral membranes (Fig. 3). The Na+, K+ -ATPase, acting in
concert with K+ channels in the basolateral membrane, establishes
and maintains the chemical and electrical gradients that are utilized
by secondary active transporters. Ouabain, an inhibitor of the Na+, K+
-ATPase, blocks cAMP-dependent net ﬂuid secretion by intact cystsCl
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Fig. 3. Transport mechanisms involved in cAMP-dependent Cl− secretion by ADPKD cyst e
secretion by a variety of secretory epithelia. The Na+, K+-ATPase is a primary (P) active trans
responsible for establishing and maintaining the chemical gradients for Na+ and K+ acros
transporter, utilizes the Na+ gradient to transport Na+, K+, 2 Cl− into the cell, raising th
(AVP V2R) is a G-protein coupled receptor (GPCR) coupled to Gs. Binding of arginine vasop
activation of the cystic ﬁbrosis transmembrane conductance regulator (CFTR) Cl− channel
the initial step in cAMP-dependent Cl− secretion. Subsequent activation of basolateral
membrane potential for Cl− transport. The combination of the apical Cl− conductance
paracellular transport of Na+. The net addition of NaCl to the luminal ﬂuid drives the osmo
1998].[95] and anion secretion by polarized ADPKD cell monolayers [96].
Several K+ channels have been shown to be present in collecting
ducts, including inward-rectifying K+ channels (Kir) [97]. These
channels are inhibited by intracellular ATP and glibenclamide, a
sulfonylurea, and are activated by cAMP. ADPKD and NHK cells were
shown to express mRNA for Kir6.2, an ATP-sensitive K+ channel [98].
Basolateral application of glibenclamide potently inhibited anion
secretion consistent with inhibition of ATP-sensitive K+ channels.
More recently, Albaqumi et al. found that KCa3.1, an intermediate
conductance Ca2+-activated K+ channel, is present in ADPKD cells
[99]. TRAM-34, a highly speciﬁc KCa3.1 blocker, inhibited cAMP-
dependent anion secretion and in vitro cyst growth of ADPKD cells.
These data demonstrate that Kir6.2 and KCa3.1 participate in cAMP-
dependent anion secretion and inhibition of these channels may have
therapeutic value in PKD.
Several lines of evidence indicate that cAMP-dependent anion
secretion is mediated by Cl− transport via apical CFTR Cl− channels
[100,101]. Measurements of intracellular Cl− during cAMP stimulation
reveal that there is an initial efﬂux of Cl−, consistent with activation of
apical CFTR channels [102]. Treatment with CFTR inhibitors blocks
cAMP-dependent anion secretion by ADPKD cell monolayers [96].
Chloride enters the cell through basolateral NKCC1, an electrically
neutral Na+-K+-2Cl− cotransporter, that brings Na+, K+ and Cl− into
the cell using the transmembrane Na+ gradient. Thus, intracellular Cl−
is maintained above its electrochemical gradient and is poised for rapid
Cl− efﬂux across the luminal membrane upon cAMP activation of CFTR.
Increases in the apical Cl− conductance and basolateral K+ conductance
create a lumen negative transepithelial electrical potential that drives
passive Na+ transport through the paracellular pathway. The net
addition of Na+ and Cl− into the luminal ﬂuid drives the osmotic
movement of water into the cyst cavity [87,103].
Fluid secretion has been difﬁcult to study in intact PKD kidneys.
Recently, Magenheimer et al. showed that cAMP induces the formation
of cyst-like dilations in embryonic Pkd1−/− kidneys using metanephric
organ cultures [104]. These dilations were eliminated by CFTR andNa
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pithelial cells. Many of these transporters and channels are involved in Cl− and ﬂuid
porter that utilizes cell energy to pump 3 Na+ out of the cell in exchange for 2 K+ and is
s the membrane. The bumetanide sensitive NKCC1, a basolateral secondary active (S)
e intracellular Cl− concentration above its electrochemical gradient. The V2 receptor
ressin (AVP) to V2R increases the synthesis of cAMP by adenylyl cyclase (AC), causing
on the apical membrane of the cells. Chloride efﬂux through apical CFTR channels is
K+ conductance, including the KCa3.1 channels, is critical to maintain the negative
and the basolateral K+ conductance creates a transepithelial potential driving the
tic movement of ﬂuid [modiﬁed from Sullivan et al. Physiological Rev 78: 1165–1191,
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that treatment with a novel CFTR inhibitor reduced cyst expansion in a
PKD mouse model [105]. These in vitro and in vivo studies suggest that
ion channels and transporters are potential therapeutic targets to block
ﬂuid accumulation in cysts of PKD kidneys.
6. Targeting cAMP-dependent cystic expansion in PKD
The discovery that cAMP has a central role in PKD has led to several
preclinical studies in PKD animals testing drugs that target renal cAMP
production and/or its downstream effectors. In this section, in vivo
studies are discussed, including approaches to reduce renal cAMP
production and targets of cAMP-dependent cell proliferation and ﬂuid
secretion.
6.1. Blocking the renal effects of vasopressin
OPC-31260, a V2R antagonist, administered to PKD animals
orthologous to human disease, including the Pkd2WS25/− mouse
(ADPKD), PCK rat (ARPKD) and pcy mouse (nephronophthisis type 3)
reduced renal cAMP and inhibited disease progression measured by
reductions in kidney volume, cystic area, number of mitotic and
apoptotic cells, and blood urea nitrogen (BUN) [47,49,106]. There was
also a corresponding reduction in the renal activity of the B-Raf/MEK/
ERK pathway. Tolvaptan, a potent and highly selective human V2R
antagonist, had a similar effect on renal cAMP and PKD progression in
ADPKD and ARPKD animal models. Wang et al. conﬁrmed that the
effect of these drugs to reduce disease progression was due to
inhibition of AVP effects by selectively knocking out AVP in the PCK rat
[107]. These animals were generated by crossing PCK rats with
Brattleboro (AVP−/−) rats which are unable to express AVP. In the
absence of AVP, the PCK mice had reduced renal cAMP accumulation,
ERK activity, cell proliferation, and ﬁbrosis andwere essentially free of
renal cysts. Administration of DDAVP by osmotic minipump restored
cystic disease in the AVP-deﬁcient PCK rats providing unequivocal
evidence for the roles of AVP and cAMP on cystic disease progression.
An alternative approach to decrease plasma AVP levels is to increase
water consumption. Increased water intake in PCK rats was shown to
be sufﬁcient to reduce renal cAMP and the activity of B-Raf/MEK/ERK
signaling. PCK rats on high water intake had reduced renal cell
proliferation, cystic area and kidney weight, and improved renal
function [55]. These animal studies strongly support the idea that
blocking the effects of AVP will provide a protective effect on the
kidneys of ADPKD patients. Tolvaptan is currently being evaluated in
ADPKD patients in an international clinical trial (TEMPO). Increased
water ingestion throughout the day to suppress AVP levels is also
being considered as an alternative approach to tolvaptan in ADPKD
patients with relatively normal GFR [55,108,109].
Somatostatin is a peptide secreted by the neuroendocrine neurons
of the hypothalamus and the alpha cells in the Islets of Langerhans in
the pancreas. The somatostatin receptor, SSTR2, is a Gi coupled
receptor present on renal epithelial cells [110]. Binding of somato-
statin to its receptor inhibits AC activity and cAMP production. Low
concentrations have been shown to antagonize the effects of AVP in
collecting ducts [111]. Octreotide, a stable long-acting somatostatin
analogue, was shown to halt kidney and liver cysts in PCK rats [112].
This drug inhibited kidney volume in a small randomized, crossover,
placebo-controlled study in ADPKD patients followed for 6 months
[113], providing support for ongoing clinical trials.
6.2. Blocking cAMP-dependent MEK/ERK signaling and cell proliferation
Several approaches to target cAMP-dependent proliferation are
being considered for inhibition of cyst expansion in ADPKD. One
strategy is to restore intracellular Ca2+ in PKD cells to prevent the
mitogenic effect of cAMP. Triptolide, a natural medicinal herb that isthought to bind and activate PC2, induces cell cycle arrest in Pkd1−/−
cells and retards renal cyst growth in Pkd1−/− kidneys [114,115]. A
similar approach to correct the defect in intracellular Ca2+ is to
activate calcium-sensing receptors (CaSR) on the plasma membrane
of renal cells. CaSR are coupled to Gq and activate phospholipase C and
protein kinase C to increase intracellular Ca2+. Extracellular Ca2+
activates CaSR and calcimimetics bind CaSR to increase the sensitivity
of the receptor to external Ca2+. The effect of calcimimetic has been
examined in three PKD models with mixed results. Wang et al. found
that treatment with a calcimimetic caused a slight reduction in
ﬁbrosis, but provided no detectable change in renal cAMP or
cystogenesis in the PCK rat and the Pkd2WS25/− mouse [116].
Consistent with this observation, the addition of calcimimetic did
not prevent cAMP-dependent proliferation of human ADPKD cells (D.
Wallace, unpublished results). Recently, Gattone et al. found the
administration of the calcimimetic R-568 in Cy/+ rats had no effect on
cyst expansion at 34 weeks, but reduced total kidney weight at 38
weeks, suggesting that calcimimetics may have a beneﬁcial effect in
PKD [117]. Based on the mixed results from these studies, it remains
to be determined if calcimimetics are renal protective in PKD.
Pharmacological activation of Trpv4, a Ca2+ entry channel,
increases Akt activity, and inhibits B-Raf and ERK in cholangiocytes
of cystic livers [26]. Treatment with GSK1016790A, a Trpv4 activator,
caused a small reduction of liver cysts of PCK rats, but the effect was
not statically signiﬁcant. By contrast, renal cyst area was markedly
reduced, indicating that activation of Trpv4 may restore the normal
cellular phenotype in PKD cells. Together, these studies suggest that
small molecules that activate Ca2+ release from intracellular stores or
stimulate Ca2+ entry may have therapeutic value in the treatment of
PKD.
Many anti-cancer drugs target the Raf/MEK/ERK pathway and cell
proliferation, and may be an attractive option for ADPKD treatment.
PD184352, a MEK inhibitor, has been through phase I and II clinical
trials for solid tumors with disappointing results [118]. The majority
of these patients had tumors caused by a Ras mutation, and it turns
out, tumors with B-Raf mutations are extremely sensitive to MEK
inhibition in comparison to tumors caused by Ras mutations [119].
Considering that constant cAMP production in cystic cells keeps B-Raf
in a constitutively activated state, MEK speciﬁc inhibitors may be an
effective treatment for ADPKD. Omori et al. showed that treatment of
pcy mice for 7 weeks with PD184352 reduced kidney weight and
cystic index, increased the renal concentrating ability consistent with
improved renal function, and lowered blood pressure [120]. On the
other hand, in a model of PKD in which cysts develop rapidly, the
delivery of the MEK inhibitor U0126 on postnatal days 4 and 7
inhibited ERK activity, but did not decrease cysts at postnatal day 14
[121]. Since cyst progression in this model occurs during renal
development, an array of mitogenic factors may be responsible for the
rapid growth of cysts, overriding ERK inhibition.
B-Raf appears to govern the mitogenic response to cAMP agonists
in ADPKD and ARPKD cells [27,52,63,79]; by contrast B-Raf is normally
inactive in normal kidneys. Thus, there is reason to think that selective
B-Raf inhibition would block cAMP-dependent proliferation of cystic
epithelial cells without affecting normal renal function. Bay 43-9006, a
small molecule Raf inhibitor, blocks cAMP-dependent ERK activation,
and inhibits ADPKD cell proliferation [122]. However, treatment of jck
mice with Bay 43-9006 did not signiﬁcantly inhibit disease progres-
sion [123]. The reason for the lack of an effect in these PKD animal
models remains unclear. Bay 43-9006 is a broad spectrum kinase
inhibitor known to inhibit the activity of many kinases. This lack of
speciﬁcity may complicate the effect on Raf kinases, or alternatively,
the drug may lack the bioavailability necessary to inhibit Raf activity
in cystic kidneys. Recent evidence demonstrates that the effect of B-
Raf inhibition on ERK is not as straightforward as originally thought.
B-Raf and Raf-1 can heterodimerize, which impacts the activity of
both kinases [124–126]. Interestingly, B-Raf inhibitors have been
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Raf-1 activation and stimulation of MEK/ERK [125,126]. Kinase-dead
B-Raf mimicked the effect of B-Raf inhibitors on ERK activation. These
observations indicate that the MEK/ERK signaling is more complex
than originally thought and may require a combination of drugs to
effectively block ERK activation and cell proliferation. Targeting Src
kinase, an intermediate between receptor activation and the Ras/Raf/
MEK/ERK pathway, may be an alternative approach. SKI-606, a Src
inhibitor, was found to decrease renal and biliary cysts in the PCK
rat and bpk mouse models [127], indicating that this may be a
pharmacological approach to block receptor kinase activity as well as
cAMP activation of the ERK pathway.
In jck mice, a PKD model with elevated renal cAMP and B-Raf/
MEK/ERK activity, treatment with roscovitine, a cyclin kinase
inhibitor, resulted in long-lasting arrest of cyst growth, inhibition of
cystic disease and improved renal function [128]. There was
dephosphorylation of Rb and a decrease in cyclin D levels, suggesting
a G1/S cell cycle block. In addition, roscovitine decreased renal cAMP
levels possibly due to improved epithelial cell differentiation. This
study also showed that roscovitine has a long-lasting effect after drug
withdrawal and was effective even with intermittent dosing, which
may be important for long term treatment of PKD.
6.3. Blocking cAMP-dependent ﬂuid secretion
Cl− dependent ﬂuid secretion is largely responsible for expanding
the cyst volume, causing disruption of the normal parenchyma and
loss of renal function. It seems reasonable that inhibition of ﬂuid
secretion would prevent the expansion of these otherwise benign
neoplasms, sparing the normal nephrons. In support of this idea,
CFTR inhibitors were shown to slow cyst development in embryonic
Pkd1−/− mouse kidney organ cultures and Pkd ﬂox/-; Ksp-Cre mice
treated for 3 days [104,105]. TRAM-34, a KCa3.1 inhibitor, inhibited
cAMP-dependent Cl− secretion by ADPKD cell monolayers, and
reduced cyst growth of ADPKD cells grown within a collagen matrix
[99]. While the effect of TRAM-34 still needs to be demonstrated in a
PKD animal model, it is interesting that TRAM-34 attenuates renal
ﬁbrosis induced by unilateral ureteral obstruction in mice and rats.
Senicapoc (ICA-17043), another KCa3.1 inhibitor is currently in
clinical trials for sickle-cell disease and has shown little or no toxicity
[129]. Other targets in the secretory pathway include the Na+, K+-
ATPase and NKCC1; however, inhibition of these transporters will likely
have side effects that would worsen PKD. NKCC1 can be inhibited by
furosemide (also known as Lasix), a potent diuretic that also blocks
apical NKCC2 in the thick ascending limb of Henle. The loss of body
water due to the diuretic effect of furosemide would be expected to
increase AVP release from the pituitary gland, and stimulate renal cAMP
production. Likewise, concentrations of ouabain necessary to inhibit the
Na+, K+-ATPase will also inhibit Na+ absorption by the kidney causing
increased water loss. Recently, ouabain, even at normal circulating
levels, was shown to bind to a unique site on the Na+, K+ ATPase
stimulating the MEK/ERK pathway independent of cAMP or growth
factors [51].
7. Concluding remarks
Studies involving human cyst epithelial cells and PKD animal
models have uncovered a central role for cAMP in the pathogenesis of
PKD. First, a reduction in intracellular Ca2+ due to mutations in the
ADPKD and ARPKD genes cause a phenotypic switch in the cellular
response to cAMP, such that cAMP stimulates the B-Raf/MEK/ERK
pathway, which may be uniquely responsible for unscheduled cell
proliferation. Furthermore, activation of ERK by cAMP may lead
to secondary events involved in cyst growth, such as stimulation of
mTOR pathway [130]. Second, cAMP stimulates transepithelial Cl−
andﬂuid secretionwhich appears to be necessary for the accumulationof ﬂuid within the cyst. Preclinical studies have indicated that
reduction of renal cAMP, elevation in intracellular Ca2+, and inhibition
of components of cell proliferation and ﬂuid secretion may have
therapeutic potential to reduced cyst growth in PKD.
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